Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2016 pubmed 39 citations

Carbamylated LL-37 as a modulator of the immune response.

Koro. Catalin C; Hellvard. Annelie A; Delaleu. Nicolas N; Binder. Veronika V; Scavenius. Carsten C; Bergum. Brith B; Główczyk. Izabela I; Roberts. Helen M HM; Chapple. Iain L C IL; Grant. Melissa M MM; Rapala-Kozik. Maria M; Klaga. Kinga K; Enghild. Jan J JJ; Potempa. Jan J; Mydel. Piotr P

Key Findings

  • LL‑37 is rapidly carbamylated by physiological cyanate levels, starting at the N‑terminal Leu‑1
  • Lysine residues (Lys‑8, Lys‑12, Lys‑15) are sequentially carbamylated, creating multiple peptide variants
  • Carbamylation markedly alters LL‑37’s structure and can switch its activity from anti‑ to pro‑inflammatory

Practical Outcomes

  • If you’re using LL‑37 supplements or therapies, high inflammation or oxidative stress could degrade its benefits. Managing systemic inflammation or using antioxidants may help preserve LL‑37’s intended effects. Be cautious about dosing LL‑37 during acute inflammatory episodes, as its activity may become counterproductive.

Summary

The study shows that the immune‑boosting peptide LL‑37 can be chemically altered by a common by‑product of inflammation called cyanate. This modification, called carbamylation, happens fast and changes the peptide’s shape, sometimes turning its anti‑inflammatory effects into pro‑inflammatory ones.

Abstract

Carbamylation of lysine residues and protein N-termini is an ubiquitous, non-enzymatic post-translational modification. Carbamylation at sites of inflammation is due to cyanate formation during the neutrophil oxidative burst and may target lysine residues within the antimicrobial peptide LL-37. The bactericidal and immunomodulatory properties of LL-37 depend on its secondary structure and cationic nature, which are conferred by arginine and lysine residues. Therefore, carbamylation may affect the biological functions of LL-37. The present study examined the kinetics and pattern of LL-37 carbamylation to investigate how this modification affects the bactericidal, cytotoxic and immunomodulatory function of the peptide. The results indicated that LL-37 undergoes rapid modification in the presence of physiological concentrations of cyanate, yielding a spectrum of diverse carbamylated peptides. Mass spectrometry analyses revealed that theN-terminal amino group of Leu-1 was highly reactive and was modified almost instantly by cyanate to generate the predominant form of the modified peptide, named LL-37(C1) This was followed by the sequential carbamylation of Lys-8, Lys-12, and Lys-15 to yield LL-37(C8), and Lys-15 to yield LL-37(C12,15) Carbamylation had profound and diverse effects on the structure and biological properties of LL-37. In some cases, anti-inflammatory LL-37 was rapidly converted to pro-inflammatory LL-37.

Study Information

Provider

pubmed

Year

2016

Date

2016-02-15T00:00:00.000Z

DOI

10.1177/1753425916631404

Citations

39

References

45